These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation. Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618 [TBL] [Abstract][Full Text] [Related]
6. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19). El-Demerdash A; Metwaly AM; Hassan A; Abd El-Aziz TM; Elkaeed EB; Eissa IH; Arafa RK; Stockand JD Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33808721 [TBL] [Abstract][Full Text] [Related]
8. An in-silico evaluation of COVID-19 main protease with clinically approved drugs. Tachoua W; Kabrine M; Mushtaq M; Ul-Haq Z J Mol Graph Model; 2020 Dec; 101():107758. PubMed ID: 33007575 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, antimicrobial, molecular docking and molecular dynamics studies of lauroyl thymidine analogs against SARS-CoV-2: POM study and identification of the pharmacophore sites. Anowar Hosen M; Sultana Munia N; Al-Ghorbani M; Baashen M; Almalki FA; Ben Hadda T; Ali F; Mahmud S; Abu Saleh M; Laaroussi H; Kawsar SMA Bioorg Chem; 2022 Aug; 125():105850. PubMed ID: 35533581 [TBL] [Abstract][Full Text] [Related]
11. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983 [TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
13. Amentoflavone derivatives significantly act towards the main protease (3CL Dey D; Hossain R; Biswas P; Paul P; Islam MA; Ema TI; Gain BK; Hasan MM; Bibi S; Islam MT; Rahman MA; Kim B Mol Divers; 2023 Apr; 27(2):857-871. PubMed ID: 35639226 [TBL] [Abstract][Full Text] [Related]
14. Interaction of Laurusides 1 and 2 with the 3C-like Protease (M Autiero I; Roviello GN Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982585 [No Abstract] [Full Text] [Related]
15. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239 [TBL] [Abstract][Full Text] [Related]
16. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes. Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845 [TBL] [Abstract][Full Text] [Related]
17. Primer for Designing Main Protease (M Thakur A; Sharma G; Badavath VN; Jayaprakash V; Merz KM; Blum G; Acevedo O J Phys Chem Lett; 2022 Jun; 13(25):5776-5786. PubMed ID: 35726889 [TBL] [Abstract][Full Text] [Related]
18. Repositioning of anti-dengue compounds against SARS-CoV-2 as viral polyprotein processing inhibitor. Bajrai LH; Faizo AA; Alkhaldy AA; Dwivedi VD; Azhar EI PLoS One; 2022; 17(11):e0277328. PubMed ID: 36383621 [TBL] [Abstract][Full Text] [Related]
19. Allosteric inhibitors of the main protease of SARS-CoV-2. Samrat SK; Xu J; Xie X; Gianti E; Chen H; Zou J; Pattis JG; Elokely K; Lee H; Li Z; Klein ML; Shi PY; Zhou J; Li H Antiviral Res; 2022 Sep; 205():105381. PubMed ID: 35835291 [TBL] [Abstract][Full Text] [Related]
20. Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2. Kodchakorn K; Poovorawan Y; Suwannakarn K; Kongtawelert P J Mol Graph Model; 2020 Dec; 101():107717. PubMed ID: 32861974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]